Drug intelligence / Profile preview

klotho protein

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

Klotho protein is an **anti-aging protein** that exists in two major forms: a **membrane-bound form** (130kDa transmembrane protein) and a **soluble form** (s-Klotho). The protein is primarily expressed in the **kidney**, with additional expression in the **brain** and **pancreas**. The membrane-bound form acts as a co-receptor for **fibroblast growth factor 23 (FGF23)** signaling and plays a crucial role in regulating **vitamin D metabolism** and **phosphate balance**. Both forms exhibit multiple pharmacological functions including **anti-inflammatory**, **anti-oxidative**, **anti-fibrotic**, and **tumor-suppressive** properties. Klotho functions through several mechanisms: it **blocks NF-κB signaling** and prevents its nuclear translocation, **suppresses TGF-β1/SMAD signaling**, **inhibits toll-like receptors (TLR2/4)**, and **reduces pro-inflammatory cytokines** (IL-6, IL-8, TNF-α). The protein also demonstrates **neuroprotective effects**, with studies showing enhanced **cognition and memory** in aged subjects. Klotho deficiency is associated with accelerated aging and various pathological conditions. As a therapeutic agent, recombinant Klotho protein has shown promising results in preclinical models for multiple conditions including **diabetic kidney disease (DKD)**, **cardiovascular diseases**, **Alzheimer's disease**, and **cancer**. The protein has a relatively **short half-life of approximately 7 hours** and is noted to be **unstable with sensitivity to freeze-thaw cycles**, which presents challenges for therapeutic development. Multiple academic institutions and biotechnology companies are investigating klotho protein therapeutically, though widespread clinical application remains in the exploratory phase. Various delivery methods are being explored including **recombinant protein administration**, **viral gene delivery**, and strategies to **upregulate endogenous production** through existing drugs like paricalcitol and sevelamer carbonate.

Brand names
soluble alpha-klotho
Other names
α-Klothoalpha-Klothosoluble Klothos-Klothorecombinant Klotho
02

Targets

NF-κBTNFRSF11A (RANK)FGF23 (Fibroblast growth factor 23)

Beyond the preview

Go deeper on klotho protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on klotho protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call